Nine fellows are an integral part of the URPP "Translational Cancer Reserach". Each of the fellows works on the interphase between different research groups and consolidate the multidisciplinary and translational character of the URPP.
Identification of molecular pathways relevant to melanoma cell biology including dissemination with focus on stem cells and the impact of conventional and novel therapies on such pathways.
(Dummer, Levesque, Schraml, Sommer; Fellow Sandra Varum).
Oncogenic Cell Invasion
Investigation of the role of developmental genes in invasion of melanoma using C.elegans, (genetically modified) melanoma cells and biobanked melanoma cultures.
(Dummer, Hajnal, Levesque, Schraml, Sommer; Fellow Evelyn Lattmann).
CAR T Cells
Generation of a versatile platform for the generation of CAR T cells directed against a variety of known and novel leukemic and hemapoietic stem cells antigens and test such CAR T cells with respect to tumor eradication and safety.
(Becher, van den Broek, Curioni, Manz, Pascolo; Fellow: Renier Myburgh).
New Therapies and Clinical Trials
Development of novel immunotherapies for cancer using preclinical models and performing three clinical trials in patients with glioblastoma, melanoma and mesothelioma.
(Becher, Boyman, van den Broek, Chahwan, Curioni, Dummer, Pascolo, Weller; Fellow Anna Rita Liuzzi).
The Role of β-catenin Signaling in Squamous Cell Carcinoma
Investigation of the role of canonical Wnt-signaling and of b-catenin transcriptional output in development and progression of SCC with a special focus on modulation of immune responses.
(Basler, van den Broek, Dummer, Moor; Fellows Tomas Valenta and Virginia Cecconi (50% each)).
Identification of epigenetic regulators in different cancer cells to understand the interplay between genetic and epigenetic alterations and to develop novel epigenome-targeted therapeutic strategies.
(Basler, Hottiger, Levesque, Manz, Schraml, Lukas Sommer; Fellow Lorenza Ferretti).
Radiation and Tissue Response
Identification of molecular pathways relevant to immune stimulation by radiotherapy to define biomarkers of response and improve clinical efficacy.
(Bodenmiller, van den Broek, Dummer, Hottiger, Levesque, Schraml; Fellow Nikiforos Kapetanakis).
Multidimensional analysis of the tumor microenvironment using CytOF and bioinformatics in relation to response to standard and immune therapy to better understand parameters that define clinical response.
(Becher, Bodenmiller, Boyman, Chahwan, Alessandra Curioni, Dummer, Levesque, Manz, Pascolo, Schraml, Weller; Fellow Nicolás Núñez).